Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/15265161.2012.692436 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Infliximab and adalimumab in the treatment of fistulizing Crohn's disease: a propensity score-matched analysis from the prospective Persistence Australian National IBD Cohort (PANIC4) study.
Am J Gastroenterol
December 2024
Department of Gastroenterology and Hepatology, Concord Repatriation General Hospital, Sydney, Australia.
Background/aims: There are spare data on comparative medication efficacy in fistulizing Crohn's disease (FCD), particularly with immunomodulator co-therapy. Persistence is a unique way to assess real-world outcomes.
Methods: The persistence of all dispensed biological agents were analysed from the Australian Pharmaceutical Benefits Scheme (PBS) registry data 2005-2021 for FCD.
Cardiovascular, kidney and safety outcomes with canagliflozin in older adults: A combined analysis from the CANVAS Program and CREDENCE trial.
Diabetes Obes Metab
January 2025
Sydney Medical School, Faculty of Medicine & Health, University of Sydney, Sydney, Australia.
Aim: SGLT2 inhibitors may be underused in older adults with type 2 diabetes due to concerns about safety and tolerability. This pooled analysis of the CANVAS Program and CREDENCE trial examined the efficacy and safety of canagliflozin according to age.
Methods: Pooled individual participant data from the CANVAS Program (n = 10 142) and CREDENCE trial (n = 4401) were analysed by baseline age (<65 years, 65 to <75 years, and ≥75 years).
Development and Validation of a Scoring System to Predict 2-Year Clinical Remission in Ulcerative Colitis Patients on Vedolizumab.
Crohns Colitis 360
January 2025
Department of Gastroenterology and Liver Services, Concord Repatriation General Hospital, Sydney, New South Wales, Australia.
Article Synopsis
- Vedolizumab is an advanced treatment option for ulcerative colitis (UC) that can be effective but can lead to a loss of response over time, prompting the need to identify predictive factors for maintaining remission.
- Researchers used logistic regression on participants from a study to create a VIEWS scoring system that assesses the likelihood of continuing remission after two years.
- The study found that factors like gender, treatment history, and baseline health status were significant predictors, with the VIEWS score showing strong accuracy in predicting remission outcomes in two different patient cohorts.
Cerebral venous sinus thrombosis after intrathecal administration of nusinersen.
BMJ Case Rep
January 2025
Neurosciences, Concord Repatriation General Hospital, Concord West, New South Wales, Australia
Cerebral venous sinus thrombosis is an uncommon sequela of low intracranial pressure, which may result from a lumbar puncture (LP). We describe a case of a patient in their 40s presenting with 48 hours of persistent headache following intrathecal administration of nusinersen for spinal muscular atrophy (SMA) type 3. There were no focal neurological signs or symptoms apart from baseline symmetrical proximal limb weakness attributed to SMA.
View Article and Find Full Text PDFClinical Pharmacology and Approach to Dose Selection of Emestedastat, a Novel Tissue Cortisol Synthesis Inhibitor for the Treatment of Central Nervous System Disease.
Clin Pharmacol Drug Dev
January 2025
Actinogen Medical Ltd, Sydney, New South Wales, Australia.
This review demonstrates the value of central pharmacodynamics (PD), including positron emission tomography (PET) and computerized cognitive testing, to supplement pharmacokinetic (PK) and peripheral PD for determining the target dose range for clinical efficacy testing of emestedastat, an 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1) inhibitor. Combined data from 6 clinical trials in cognitively normal volunteers and patients with Alzheimer disease included a population PK model, endocrine PD, a human PET trial (11β-HSD1 brain imaging), and computerized cognitive testing. PK and PET findings were similar in volunteers and patients with Alzheimer disease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!